Related Experiment Video

Updated: Jun 3, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Impact of KRAS Mutations on Management of Colorectal Carcinoma

Kevin M Sullivan1, Peter S Kozuch

  • 1Department of Medicine, Section of Hematology/Oncology, Albert Einstein College of Medicine, Beth Israel Medical Center, Phillips Ambulatory Care Center, 10 Union Square East, Suite 4C, NY 10003, USA.

Pathology Research International
|March 26, 2011
PubMed

Insights

This study explores resistance to epidermal growth factor receptor (EGFR) antagonists in colorectal cancer (CRC). It discusses mechanisms and strategies, including novel therapies, to improve treatment outcomes for patients with KRAS wild-type tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The epidermal growth factor receptor (EGFR) pathway is a key target in colorectal cancer (CRC) treatment.
  • EGFR antagonists show efficacy, but only a subset of patients benefit.
  • KRAS wild-type (WT) status is essential but not always sufficient for treatment response.

Purpose of the Study:

  • To discuss mechanisms of primary resistance to anti-EGFR monoclonal antibody therapy in KRAS WT colorectal cancer.
  • To explore strategies for overcoming resistance, including novel agents and combination therapies.
  • To review the application of anti-EGFR monoclonal antibodies in neoadjuvant and adjuvant settings.

Main Methods:

  • Literature review and synthesis of current research on EGFR pathway inhibitors in CRC.
  • Analysis of resistance mechanisms in KRAS WT colorectal cancer.
  • Exploration of emerging therapeutic strategies and clinical trial data.

Main Results:

  • Primary resistance to anti-EGFR therapy in KRAS WT CRC is multifactorial.
  • Novel therapeutic agents and combination strategies show promise in overcoming resistance.
  • The use of anti-EGFR antibodies in neoadjuvant and adjuvant settings is an active area of investigation.

Conclusions:

  • Understanding and overcoming resistance mechanisms are critical for improving anti-EGFR therapy efficacy in CRC.
  • Targeting resistance pathways and exploring novel therapeutic combinations are essential for advancing CRC treatment.
  • Further research is needed to optimize the use of anti-EGFR antibodies in various clinical settings.

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...